Latest Intellectual Property News

EZZ Life Science Holdings has secured a four-year exclusive global distribution agreement with Aumake Limited, committing to at least A$10 million in purchases. This partnership aims to accelerate EZZ’s international reach while preserving brand control.

Nanoveu Limited has secured exclusive evaluation rights to four cutting-edge autonomous drone navigation technologies from Nanyang Technological University, aiming to advance GPS-free multi-drone coordination and endurance.

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

BrainChip has launched its AKD2500 silicon development project, advancing its Akida™ 2.0 neuromorphic AI platform with a $2.5 million investment and prototype expected by Q3 2026.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.

iCandy Interactive’s subsidiary Lemon Sky Studios has appointed a seasoned industry leader to drive global partnerships, secured over A$1 million in recent contracts, and is exploring strategic options to unlock shareholder value.

Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

Critical Resources Limited has launched a six-month evaluation program in partnership with the South Dakota School of Mines & Technology to develop next-generation solid-state lithium-ion battery materials, aiming to reduce technical risks and accelerate prototype development.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

Electro Optic Systems (EOS) has firmly rejected allegations from a recent Grizzly Research report, highlighting its strengthened financial position, significant contract wins, and strategic acquisition to bolster its defence technology portfolio.